Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

206 ta ish

Ish: Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

  1. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies

    Ding-Ya Sun, Yijie Hu, Xin Li +3

    Sharh maqola202412 iqtibos
    ABI

  2. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

    Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

    Sharh maqola20259 iqtibos
    ABI

  3. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers

    Wei-Xin Xu, Qiang Qu, Hai-Hui Zhuang +5

    Maqola20248 iqtibos
    ABI

  4. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Maqola20217 iqtibos
    ABI

  5. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions

    Chou‐Yi Hsu, Shavan Askar, Samer Saleem Alshkarchy +7

    MaqolaOchiq kirishRadiomics and Machine Learning in Medical ImagingClinical and Experimental Medicine20255 iqtibos
    ABI

  6. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

    Xinyi Xiao, Shengkang Huang, Sifei Chen +4

    Sharh maqolaOchiq kirish20215 iqtibos
    ABI

  7. Multidrug resistance in cancer: role of ATP–dependent transporters

    Michael M. Gottesman, Tito Fojo, Susan E. Bates

    Sharh maqola20025 iqtibos
    ABI

  8. Sarlavhasiz

    Boshqa5 iqtibos
    ABI

  9. Harnessing bacteria for tumor therapy: Current advances and challenges

    Lina Guo, Jinsong Ding, Wenhu Zhou

    Maqola20234 iqtibos
    ABI

  10. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

    Maqola20214 iqtibos
    ABI

  11. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos +80

    Sharh maqola20224 iqtibos
    ABI

  12. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

    Margot J. Pont, Tyler Hill, Gabriel O. Cole +14

    MaqolaOchiq kirish20193 iqtibos
    ABI

  13. Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma

    Sylvain Simon, Stanley R. Riddell

    Boshqa20203 iqtibos
    ABI

  14. Precision sniper for solid tumors: CAR-NK cell therapy

    Sisi Li, Jiajie Jing, Yueming Chen +6

    Sharh maqola20253 iqtibos
    ABI

  15. Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies

    Annamaria Salvati, Viola Melone, Alessandro Giordano +12

    Sharh maqolaOchiq kirish20252 iqtibos
    ABI

  16. GPRC5D-Targeted CAR T Cells for Myeloma

    Sham Mailankody, Sean M. Devlin, Jonathan Landa +35

    MaqolaOchiq kirish20222 iqtibos
    ABI

  17. Off-the-Shelf Chimeric Antigen Receptor T Cells

    Norihiro Watanabe, Maksim Mamonkin

    Sharh maqolaOchiq kirish20212 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  19. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michèle Cavo, Evangelos Terpos, Cristina Nanni +25

    Sharh maqola20172 iqtibos
    ABI

  20. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

    Sumin Jo, Shipra Das, Alan F. Williams +19

    Maqola20222 iqtibos
    ABI

  21. Liquid chromatography–tandem mass spectrometry for clinical diagnostics

    Stefani N. Thomas, Deborah French, Paul J. Jannetto +2

    Sharh maqola20222 iqtibos
    ABI

  22. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

    Robert A. Kyle, Ellen D. Remstein, Terry M. Therneau +9

    Maqola20072 iqtibos
    ABI

  23. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquín Martínez‐López, Juan José Lahuerta, François Pépin +21

    Maqola20142 iqtibos
    ABI

  24. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

    S. Vincent Rajkumar, Robert A. Kyle, Terry M. Therneau +7

    Maqola20052 iqtibos
    ABI

  25. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

    Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung +1

    Boshqa20162 iqtibos
    ABI